Latest News & Features
Europe
The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds. 11 June 2026
Careers
The opportunity to grow a “powerhouse IP litigation practice in the heart of New York” was behind the lateral move of highly experienced litigators to Morrison Foerster. 11 June 2026
Americas
Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit. 10 June 2026
Americas
A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector. 9 June 2026
Europe
In the second of a series of interviews with women judges at the Unified Patent Court, Carine Gillet shares her views with Sarah Speight on encouraging more women into technical judicial careers, how equipped the court is to handle life sciences disputes, and more. 9 June 2026
Careers
The data and intelligence firm appoints the former CEO of CPA Global—which Clarivate bought in 2020—to lead the IP division’s growth, as the global company aims to accelerate AI integration and streamline its core business operations. 9 June 2026
Americas
Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents. 8 June 2026
Careers
Known for his work on major pharmaceutical patent disputes and landmark SEP cases, the London-based litigator has joined a new firm as partner. 8 June 2026
Americas
Justices refuse to place generic drug makers “between a rock and a hard place,” in a landmark ruling clarifying induced patent infringement in pharma. 4 June 2026
Biotechnology
The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs. 4 June 2026